Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01498978 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions

BIOLOGICAL: ipilimumab
OTHER: laboratory biomarker analysis

Sponsor

OHSU Knight Cancer Institute

Collaborators

[object Object]
[object Object]